Opus Genetics (IRD)
3.82
-0.30 (7.28%)
Upcoming Events
Latest Headlines
Form 8-K Opus Genetics, Inc. For: Oct 19
October 21, 2026 4:06 PM - SEC Filing
FDA clears Opus Genetics IND for RDH12 childhood blindness therapy
October 21, 2026 7:03 AM - StreetInsider
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
October 21, 2026 7:00 AM - Globe NewsWire
Opus Genetics (IRD) Reiterated at Market Outperform by Citizens on VTRS' Position, Commercial Strength
October 19, 2026 4:26 AM - StreetInsider
FDA approves Opus Genetics' eye drop RYZUMVI for presbyopia
October 16, 2026 12:00 PM - StreetInsider
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
October 16, 2026 12:00 PM - Globe NewsWire
Opus Genetics (IRD) Reiterated at Market Outperform by Citizens on Key Learnings from BEST1 Cohort
October 16, 2026 4:52 AM - StreetInsider
Form 8-K Opus Genetics, Inc. For: Oct 14
October 15, 2026 5:23 PM - SEC Filing
Opus Genetics reports gene therapy trial data for two eye diseases
October 15, 2026 4:00 PM - StreetInsider
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
October 15, 2026 4:00 PM - Globe NewsWire
Opus Genetics to Present at the Chardan Annual Healthcare Conference
October 13, 2026 7:00 AM - Globe NewsWire
Form 4 Opus Genetics, Inc. For: Sep 30 Filed by: Foundation Fighting Blindness Retinal Degeneration Fund
October 2, 2026 7:47 PM - SEC Filing
Form 4 Opus Genetics, Inc. For: Sep 09 Filed by: Magrath George
September 11, 2026 4:10 PM - SEC Filing
Form 8-K Opus Genetics, Inc. For: Sep 11
September 11, 2026 7:48 AM - SEC Filing
Big Pharma Setbacks Create a New Wave of Rebound Plays
September 10, 2026 2:13 PM - StreetInsider
Opus Genetics (IRD) PT Raised to $17 at Citizens
September 9, 2026 12:31 PM - StreetInsider
Opus Genetics (IRD) PT Raised to $13 at Wedbush
September 9, 2026 12:25 PM - StreetInsider
Four Biotech Stories Heating Up Right Now
September 9, 2026 11:56 AM - StreetInsider
Opus Genetics reports early positive data from gene therapy eye trial
September 9, 2026 7:07 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Opus Genetics (IRD)
September 8, 2026 7:38 AM - StreetInsider
Opus Genetics (IRD) Reiterated at Market Outperform by Citizens: Focus on Viatris
August 28, 2026 4:42 AM - StreetInsider
Longeveron names Nirav Jhaveri as CFO
August 19, 2026 4:05 PM - StreetInsider
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
August 19, 2026 4:05 PM - Globe NewsWire
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 19, 2026 4:01 PM - Globe NewsWire
TD Cowen on Opus Genetics (IRD): 'High Conviction For Meaningful Efficacy'
August 19, 2026 9:14 AM - StreetInsider
Opus Genetics (IRD) Reiterated at Market Outperform by Citizens Ahead of Phase 1/2 BIRD-1 Trial
August 19, 2026 4:31 AM - StreetInsider
Form EFFECT Opus Genetics, Inc.
August 17, 2026 6:18 AM - SEC Filing
Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: PERCEPTIVE ADVISORS LLC
August 14, 2026 5:23 PM - SEC Filing
Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: Caligan Partners LP
August 14, 2026 4:40 PM - SEC Filing
Form SCHEDULE 13G/A Opus Genetics, Inc. Filed by: BALYASNY ASSET MANAGEMENT L.P.
August 14, 2026 6:14 AM - SEC Filing
Opus Genetics (IRD) PT Lowered to $9 at RBC Capital
August 7, 2026 7:30 AM - StreetInsider
Form S-3 Opus Genetics, Inc.
August 7, 2026 6:22 AM - SEC Filing
Form 10-Q Opus Genetics, Inc. For: Jun 30
August 6, 2026 4:37 PM - SEC Filing
Opus Genetics, Inc. (IRD) Tops Q2 EPS by 2c
August 6, 2026 7:37 AM - StreetInsider
Form 8-K Opus Genetics, Inc. For: Aug 06
August 6, 2026 7:05 AM - SEC Filing
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
August 6, 2026 7:01 AM - Globe NewsWire
Opus Genetics completes enrollment in phase 3 eye gene therapy trial
August 3, 2026 7:00 AM - StreetInsider
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
August 3, 2026 7:00 AM - Globe NewsWire
TD Cowen Starts Opus Genetics (IRD) at Buy
July 29, 2026 5:29 AM - StreetInsider
Form 4 Opus Genetics, Inc. For: Jul 23 Filed by: YERXA BENJAMIN R
July 27, 2026 4:08 PM - SEC Filing
Form 4 Opus Genetics, Inc. For: Jul 23 Filed by: SCHACHLE JOSEPH K
July 27, 2026 4:08 PM - SEC Filing
Form 4 Opus Genetics, Inc. For: Jul 23 Filed by: Magrath George
July 27, 2026 4:07 PM - SEC Filing
Form 4 Opus Genetics, Inc. For: Jul 23 Filed by: Gagnon Robert E.
July 27, 2026 4:07 PM - SEC Filing
Full Article List
